Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors

Joshua Williams, Rachael Lansdown, Robert Sweitzer, Marek Romanowski, Rachel LaBell, Rajan Ramaswami, Evan C Unger

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Camptothecin-based drugs, because of their poor solubility and labile lactone ring, pose challenges for drug delivery. The purpose of this research was to develop a nanoparticle delivery system for camptotheca alkaloids. After initial investigations SN-38 was selected as the candidate camptotheca alkaloid for further development. Nanoparticles comprising SN-38, phospholipids and polyethylene glycol were developed and studied in vitro and in vivo. The SN-38 formulations were stable in human serum albumin and high lactone concentrations were observed even after 3 h. In vivo studies in nude mice showed prolonged half-life of the active (lactone form) drug in whole blood and increased efficacy compared to Camptosar® in a mouse xenograft tumor model.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalJournal of Controlled Release
Volume91
Issue number1-2
DOIs
StatePublished - Aug 28 2003

Fingerprint

irinotecan
Topoisomerase Inhibitors
Infusion Pumps
Nanoparticles
Camptotheca
Lactones
Alkaloids
Pharmaceutical Preparations
Camptothecin
Heterografts
Nude Mice
Serum Albumin
Solubility
Half-Life
Phospholipids
Research

Keywords

  • Efficacy
  • Formulation
  • Lactone stability
  • Nanoparticle
  • SN-38

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. / Williams, Joshua; Lansdown, Rachael; Sweitzer, Robert; Romanowski, Marek; LaBell, Rachel; Ramaswami, Rajan; Unger, Evan C.

In: Journal of Controlled Release, Vol. 91, No. 1-2, 28.08.2003, p. 167-172.

Research output: Contribution to journalArticle

Williams, Joshua ; Lansdown, Rachael ; Sweitzer, Robert ; Romanowski, Marek ; LaBell, Rachel ; Ramaswami, Rajan ; Unger, Evan C. / Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. In: Journal of Controlled Release. 2003 ; Vol. 91, No. 1-2. pp. 167-172.
@article{4863f216942f4aa394da21dcd569f5cd,
title = "Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors",
abstract = "Camptothecin-based drugs, because of their poor solubility and labile lactone ring, pose challenges for drug delivery. The purpose of this research was to develop a nanoparticle delivery system for camptotheca alkaloids. After initial investigations SN-38 was selected as the candidate camptotheca alkaloid for further development. Nanoparticles comprising SN-38, phospholipids and polyethylene glycol were developed and studied in vitro and in vivo. The SN-38 formulations were stable in human serum albumin and high lactone concentrations were observed even after 3 h. In vivo studies in nude mice showed prolonged half-life of the active (lactone form) drug in whole blood and increased efficacy compared to Camptosar{\circledR} in a mouse xenograft tumor model.",
keywords = "Efficacy, Formulation, Lactone stability, Nanoparticle, SN-38",
author = "Joshua Williams and Rachael Lansdown and Robert Sweitzer and Marek Romanowski and Rachel LaBell and Rajan Ramaswami and Unger, {Evan C}",
year = "2003",
month = "8",
day = "28",
doi = "10.1016/S0168-3659(03)00241-4",
language = "English (US)",
volume = "91",
pages = "167--172",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors

AU - Williams, Joshua

AU - Lansdown, Rachael

AU - Sweitzer, Robert

AU - Romanowski, Marek

AU - LaBell, Rachel

AU - Ramaswami, Rajan

AU - Unger, Evan C

PY - 2003/8/28

Y1 - 2003/8/28

N2 - Camptothecin-based drugs, because of their poor solubility and labile lactone ring, pose challenges for drug delivery. The purpose of this research was to develop a nanoparticle delivery system for camptotheca alkaloids. After initial investigations SN-38 was selected as the candidate camptotheca alkaloid for further development. Nanoparticles comprising SN-38, phospholipids and polyethylene glycol were developed and studied in vitro and in vivo. The SN-38 formulations were stable in human serum albumin and high lactone concentrations were observed even after 3 h. In vivo studies in nude mice showed prolonged half-life of the active (lactone form) drug in whole blood and increased efficacy compared to Camptosar® in a mouse xenograft tumor model.

AB - Camptothecin-based drugs, because of their poor solubility and labile lactone ring, pose challenges for drug delivery. The purpose of this research was to develop a nanoparticle delivery system for camptotheca alkaloids. After initial investigations SN-38 was selected as the candidate camptotheca alkaloid for further development. Nanoparticles comprising SN-38, phospholipids and polyethylene glycol were developed and studied in vitro and in vivo. The SN-38 formulations were stable in human serum albumin and high lactone concentrations were observed even after 3 h. In vivo studies in nude mice showed prolonged half-life of the active (lactone form) drug in whole blood and increased efficacy compared to Camptosar® in a mouse xenograft tumor model.

KW - Efficacy

KW - Formulation

KW - Lactone stability

KW - Nanoparticle

KW - SN-38

UR - http://www.scopus.com/inward/record.url?scp=0141955909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141955909&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(03)00241-4

DO - 10.1016/S0168-3659(03)00241-4

M3 - Article

C2 - 12932648

AN - SCOPUS:0141955909

VL - 91

SP - 167

EP - 172

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-2

ER -